Galactooligosaccharide Mediates NF-κB Pathway to Improve Intestinal Barrier Function and Intestinal Microbiota
Molecules · 15.11.2023 · 28 (22) · 7611
DOI: 10.3390/molecules28227611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 15.11.2023. Verfasst von Menglu Xi und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shaanxi Province Key Research and Development Project, Xianyang City Key Research and Development Project, School-Enterprise Cooperation Project.
Abstract (Originalsprache)
The use of antibiotics to treat diarrhea and other diseases early in life can lead to intestinal disorders in infants, which can cause a range of immune-related diseases. Intestinal microbiota diversity is closely related to dietary intake, with many oligosaccharides impacting intestinal microorganism structures and communities. Thus, oligosaccharide type and quantity are important for intestinal microbiota construction. Galactooligosaccharides (GOS) are functional oligosaccharides that can be supplemented with infant formula. Currently, information on GOS and its impact on intestinal microbiota diversity and disorders is lacking. Similarly, GOS is rarely reported within the context of intestinal barrier function. In this study, 16S rRNA sequencing, gas chromatography, and immunohistochemistry were used to investigate the effects of GOS on the intestinal microbiota and barrier pathways in antibiotic-treated mouse models. The results found that GOS promoted Bifidobacterium and Akkermansia proliferation, increased short-chain fatty acid levels, increased tight junction protein expression (occludin and ZO-1), increased secretory immunoglobulin A (SIgA) and albumin levels, significantly downregulated NF-κB expression, and reduced lipopolysaccharide (LPS), interleukin-IL-1β (IL-1β), and IL-6 levels. Also, a high GOS dose in ampicillin-supplemented animals provided resistance to intestinal damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China.
- Shaanxi Sheep Milk Product Quality Supervision and Inspection Center, Xi'an 710000, China.
Förderung
- Shaanxi Province Key Research and Development Project
- Xianyang City Key Research and Development Project
- School-Enterprise Cooperation Project
Zitieren
APA
Xi, M., Hao, G., Yao, Q., Duan, X., & Ge, W. (2023). Galactooligosaccharide Mediates NF-κB Pathway to Improve Intestinal Barrier Function and Intestinal Microbiota. Molecules, 28(22), 7611. https://doi.org/10.3390/molecules28227611
Vancouver
Xi M, Hao G, Yao Q, Duan X, Ge W. Galactooligosaccharide Mediates NF-κB Pathway to Improve Intestinal Barrier Function and Intestinal Microbiota. Molecules. 2023;28(22):7611. doi:10.3390/molecules28227611
BibTeX
@article{Xi2023,
author = {Xi, Menglu and Hao, Guo and Yao, Qi and Duan, Xuchang and Ge, Wupeng},
title = {Galactooligosaccharide Mediates NF-κB Pathway to Improve Intestinal Barrier Function and Intestinal Microbiota},
journal = {Molecules},
year = {2023},
volume = {28},
number = {22},
pages = {7611},
doi = {10.3390/molecules28227611}
}
EUVIMED